explore -WSS

explore

author：hotspot 2025-09-28 00:51:04 - browse：86316

LONDON — Seeking to build up its pharma business, the Japanese conglomerate Asahi Kasei is moving to buy Swedish biotech Calliditas Therapeutics in a nearly $1.1 billion cash deal, the companies said Tuesday.

The firm’s offer of $19.68 per share amounts to an 83% premium versus Calliditas’ closing price on a Swedish exchange Monday. The Calliditas board has unanimously recommended that shareholders accept the offer, the company said, adding that it “aims to realize the benefits of being part of a larger platform” by being acquired.

Calliditas has an approved drug on the U.S. market called Tarpeyo, which treats a kidney disease called IgA nephropathy. The condition has in recent years attracted interest from a number of pharma companies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： 5 dead in mass shooting on Caribbean island of St. Vincent: Police

WSS

Hospitals use virtual reality to design more inclusive rooms for kids

Sanders wants to replace patents with prizes for drug inventions

Discs beat pads, tampons for heavy menstrual flow, new study shows

Germany receives 178 compensation applications from gay servicepeople over discrimination

More regulation could be coming for drug ads

Judge denies Trump's request for new trial in E. Jean Carroll case

Wikipedia

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

In age of alternative facts, a scholarly course on calling out crap

Are infertility treatments 'essential' during the Covid

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Astronauts get first look at the spacecraft that will fly them around the moon

State Dept. review finds Biden bears some blame for Afghanistan failures

'Golden Bachelor' Gerry Turner reveals what he wants in a partner and more

Malaria cases in Florida and Texas: Here’s what you need to know

NYC struggling to keep up with demand of supporting asylum seekers, Mayor Adams says

Walensky prepares to leave CDC — and Congress — behind

Hospitals use virtual reality to design more inclusive rooms for kids

hotspot

Germany receives 178 compensation applications from gay servicepeople over discrimination

In venture capital firm's success, lessons for turning crisis into profit

Lessons Learned: This is why you network to find that industry job you want

In venture capital firm's success, lessons for turning crisis into profit

Hospitals use virtual reality to design more inclusive rooms for kids

Jan. 6 charges against Trump would add to his mounting legal peril as he campaigns for 2024

entertainment

entertainment

knowledge

explore